AD-214 is under clinical development by AdAlta and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AD-214’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 25 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AD-214 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AD-214 overview

AD-214 is under development for the treatment of interstitial lung disease, fibrotic diseases including idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, wet macular degeneration, kidney fibrosis, interstitial lung disease, hypertrophic scars, chronic kidney disease, collagen-vascular disease (CVD), fibrotic non-specific interstitial pneumonia (fNSIP) or chronic fibrosing hypersensitivity pneumonitis (cHP) and unspecified cancer. It is an Fc-Fusion protein containing two AD-114 i-body molecules at the front end that binds with CXCR4 and an Fc Fragment in the tail region. It is administered via parenteral, intravenous and inhalational route. The therapeutic candidate is developed based on i-body technology.

AdAlta overview

AdAlta formerly AdAlta, is a biotechnology company. It discovers and develops new class of protein therapeutics for use in treating serious diseases. The company’s lead i-body drug candidate, AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules that binds to the human target CXCR4, and demonstrates anti-fibrotic effects in treating a type of fibrosis of the lung, known as idiopathic pulmonary fibrosis (IPF). Its i-body products are developed using proprietary technology platform that delivers specific biologics and affinity against a variety of therapeutic and diagnostic targets such as cell surface, membrane spanning and complex proteins. AdAlta utilizes the i-body technology to create a pipeline of new drugs for treating fibrotic diseases. The company collaborates with various pharmaceutical and biotech companies in Australia. AdAlta is headquartered in Melbourne, Victoria, Australia.

Quick View AD-214 LOA Data

Report Segments
  • Innovator
Drug Name
  • AD-214
Administration Pathway
  • Inhalational
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Musculoskeletal Disorders
  • Oncology
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.